Chronoscale Holdings Corp quarterly report, Q1 FY2014

Ekso Bionics Holdings, Inc. — Q1 2014 Form 10-Q

Reporting period: Three months ended March 31, 2014; financial statements are unaudited. The filing is for Ekso Bionics Holdings, Inc., not Chronoscale Holdings Corp. On January 15, 2014, Ekso Bionics, Inc. merged into the public holding company in a reverse merger; Ekso Bionics was the accounting acquirer. Accordingly, the reported historical results reflect Ekso Bionics, and comparisons may not be fully comparable to the pre-merger public company.

Business context and financial performance

Ekso designs and sells wearable robotic exoskeletons, principally for medical rehabilitation, and provides engineering services for research, development and government projects. It also has a military-development collaboration with Lockheed Martin. Management reported more than 60 medical devices sold as of March 31, 2014.

MetricQ1 2014Q1 2013
Revenue$1.06 million$696,249
Gross profit / margin$479,483 / 45%$116,472 / 17%
Operating expenses$4.37 million$3.27 million
Operating loss$3.89 million$3.15 million
Net loss$81.77 million$3.80 million
Basic and diluted loss per share$1.22$0.18
Cash used in operating activities$5.56 million$2.36 million

Revenue increased 52% year over year: medical-device revenue rose 58% to $526,753, while engineering-services revenue rose 47% to $534,958. Gross margin improved as engineering-services costs declined. Sales and marketing expense increased 26%; general and administrative expense increased 83%, including merger-related professional fees and higher employee costs. Research and development expense decreased 17%.

The net loss included a $77.44 million non-cash loss from remeasurement of warrants issued in connection with the merger and private placement. Excluding this item, the reported net loss would still reflect the $3.89 million operating loss and other net expenses. The warrant liability, valued using a Level 3 model, was $88.05 million at quarter-end; changes in its estimated fair value can materially affect reported earnings.

Financial position, liquidity and capital

  • Cash was $14.58 million at March 31, 2014, versus $805,306 at December 31, 2013. Working capital was $13.2 million.
  • Operating cash outflow of $5.56 million and investing cash outflow of $145,000 were more than offset by $19.48 million of financing cash flow. The financing included approximately $22.0 million of net common-stock proceeds, partly offset by $2.53 million of debt payments.
  • Total assets were $21.80 million; total liabilities were $96.34 million, including the $88.05 million warrant liability. Stockholders’ deficit was $74.54 million, and accumulated deficit was $119.80 million.
  • Convertible bridge notes were converted into equity and the senior notes were repaid in connection with the transaction. Remaining notes payable were approximately $151,000 at quarter-end.
  • The January–February private placement raised $25.3 million in cash, in addition to conversion of $5.0 million of bridge notes into units. The company had 78,480,019 common shares outstanding at March 31, 2014; warrants and equity awards create potential dilution.

Outlook, risks and unusual matters

  • Management stated that cash resources were expected to fund the business plan, operations, R&D and obligations through at least mid-2015, and that additional capital would be needed thereafter. There is no assurance financing will be available on acceptable terms; failure to raise funds could require significant cost reductions or curtailment of operations.
  • For the next four quarters, management expected approximately $8.0 million in sales and marketing spending, including regulatory and clinical costs, and approximately $9.5 million in general and administrative spending, described as supporting ongoing R&D efforts.
  • Management identified risks including product commercialization and sales execution, reimbursement, medical-device regulation, competition, intellectual-property protection, financing needs, and dependence on government and collaboration projects. Results may fluctuate with the timing of device deliveries, training and engineering work.
  • Disclosure controls and procedures were not effective as of March 31, 2014. Material weaknesses included prior deficiencies in audit-committee independence, cash controls and IT controls. Remediation was underway but incomplete.
  • The filing reported no material legal proceedings and no material changes to previously disclosed risk factors. The company also reported foreign-currency exposure on some international sales and no hedging agreements.
  • The filing states that the company had not filed all required Exchange Act reports during the preceding 12 months and had not submitted and posted all required Interactive Data Files; investors should review the filing-status disclosures.

Material changes versus the prior comparable period

Revenue and gross profit increased, while operating losses widened as operating expenses rose. Operating cash use more than doubled. The much larger net loss was chiefly attributable to the non-cash warrant remeasurement following the merger and financing, rather than a comparable increase in operating losses. The merger, private placement, conversion of preferred stock and bridge notes, and repayment of senior debt substantially changed the company’s capital structure and liquidity.

Important facts for investors to verify

  • Confirm the warrant valuation assumptions and the potential earnings volatility and dilution from the outstanding warrants.
  • Assess the cash runway against the company’s spending plans, expected operating cash use and stated need for financing after mid-2015.
  • Review the status and effectiveness of remediation for the disclosed material weaknesses and ineffective disclosure controls.
  • Track medical-device sales, deferred revenue and costs, customer concentration, and the timing and continuity of government and engineering-services contracts.
  • Reconcile the cover-page share count of 78,488,019 as of April 30, 2014 with the 78,480,019 shares reported outstanding at March 31, 2014.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.